The WHO has given a green light to widespread use of GlaxoSmithKline's malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The RTS,S/AS01 vaccine ...

The team think this helps the immune system to focus on malaria rather than the hepatitis. The success of the GSK vaccine has partly paved the way for Oxford to be optimistic of having their ...

Both of the malaria vaccines prequalified by the World Health Organisation (WHO) and recommended for use in children are pre-erythrocytic. These are GSK’s Mosquirix (recommended since 2021 ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Other FP9 and MVA polyprotein constructs including combination vaccines with CS and LSA1 antigens are being developed at the University of Oxford with the European Malaria Vaccine Initiative (EMVI ...

GSK's former head of vaccines R&D ... of next-generation adjuvants and their inclusion in vaccines for pandemic influenza, malaria and shingles before leaving the company in 2021.

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Expert Rev Vaccines. 2008;7(2):223-240. ME-TRAP Oxford University, MVI, Wellcome Trust Multiepitope string expressed in fowlpox and MVA Liver stage IIb CS + LSA1 epitope in attenuated viruses ...